aTyr Pharma Receives Fast Track Designation for Efzofitimod
aTyr Pharma received a Fast Track designation for its investigational candidate efzofitimod in the treatment of patients with systemic sclerosis-associated interstitial lung disease.
Efzofitimod is an immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states through selective modulation of the protein neuropilin-2, the company said.
The investigational treatment also received Fast Track designation from the FDA in August for the treatment of patients with pulmonary sarcoidosis, a form of interstitial lung disease.
The FDA’s Fast Track designation helps facilitate development and expedite the review of drugs to treat serious or life-threatening diseases with unmet need.
aTyr Pharma
aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.
September 14, 2022
